Products
- Anti-Obesity Compound Library
- GPCR/G Protein-Targeted Compounds
- Immunology/Inflammation-Targeted Compounds
- JAK/STAT-Targeted Compounds
- MAPK-Targeted Compounds
- Membrane Transporter/Ion Channel-Targeted Compounds
- Metabolism-Targeted Compounds
- NF-κB-Targeted Compounds
- Microbiology/Virology-Targeted Compounds
- Neuronal Signaling-Targeted Compounds
- Oxidation-reduction-Targeted Compounds
- PI3K/Akt/mTOR-Targeted Compounds
- Proteases/Proteasome-Targeted Compounds
- Stem Cells/Wnt-Targeted Compounds
- Tyrosine Kinase/Adaptors-Targeted Compounds
- Ubiquitin-Targeted Compounds
Online Inquiry
PF-04691502
Cat. No.:
OB0225LY-0470
Appearance:
Solid
Purity:
≥98%
Identity:
Confirmed by NMR, HPLC, and LC-MS.
Size:
Product Overview
Description:
PF-04691502 is a p70S6K inhibitor that is primarily used to inhibit cell growth and proliferation.
Synonym:
PF4691502; 1013101-36-4; 2-Amino-8-((1R,4R)-4-(2-hydroxyethoxy)cyclohexyl)-6-(6-methoxypyridin-3-yl)-4-methylpyrido[2,3-d]pyrimidin-7(8H)-one; 2-Amino-8-[4-(2-hydroxyethoxy)cyclohexyl]-6-(6-methoxypyridin-3-yl)-4-methylpyrido[2,3-d]pyrimidin-7-one
CAS No.:
1013101-36-4
Compound CID:
25033539
Formula:
C22H27N5O4
Formula Weight:
425.48
Specification
Relative Density:
1.36 g/cm3
Stability:
3 years in powder form.
Storage:
Storage at -20°C.
Applications:
PF-04691502 can be used to study cancer cell metabolic pathways or play an important role in metabolism-related disease research.
Library Information
Targets:
PIKKs; PI3K class I subunits
Receptors:
mTOR; P-Akt (S473); PI3Kα; PI3Kβ; PI3Kγ; PI3Kδ
Pathways:
Cytoskeletal signaling; Autophagy; PI3K/Akt/mTOR signaling
Plate Number:
AOCL-7
Plate Location:
a8
Empty Location:
a1-h1; a12-h12
Container:
96-well plate
Formulation:
10 mM DMSO
DMSO Max Solubility:
4.26 mg/mL; 10 mM
Water Max Solubility:
<1 mg/mL (insoluble or slightly soluble)
Ethanol Max Solubility:
<1 mg/mL (insoluble or slightly soluble)
ALogP:
1.616
HBA_Count:
6
HBD_Count:
2
Rotatable Bond:
6
